News

Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications.  Click here for more information.

|

Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications.  Click here for more information.  

Services

Monoclonal Antibody Discovery

Antibody discovery by hybridoma and phage display technologies, combined with computer-aided antibody design (CAAD).

Antibody discovery by hybridoma technology.
Use CAAD to identify epitopes exposed on antigens. Design and implement immunization strategies based on target biology, 3D information and bioinformatics. HT binding, functional, and epitope binning assays to screen the best antibodies. Apply CAAD to select candidates with good developability features.

Antibody screening with phage display technology.
Human naïve ScFv, Llama naïve, and Llama humanized VHH libraries are used to discover hits. CAAD is used to select candidates with good developability features such as less aggregation, less PTMs, and low immunogenicity.

Lead selection.
Candidates with best safety, efficacy, and developability balance are selected as leads.

3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA